020 7407 3100

General News

London Bridge Hospital to offer NanoKnife (Irreversible Electroporation) treatment to Pancreatic and Liver Cancer patients

The technology- Irreversible Electroporation-  uses high-voltage electricity to ‘kill’ tumours. It is known by popular name “ Nanoknife” as it destroys tumours by creating nano pores into cell membranes which results in cancer cell death .
London Bridge Hospital  is already a major centre for the treatment of pancreatic and liver tumours, and NanoKnife is a less invasive treatment option for patients not suitable for traditional surgery.
NanoKnife uses needles which are guided into position around the tumour using ultrasound or CT scans. In some patients the procedure is performed intra-operatively using a small incision to expose  the tumour.
Once the needles are in the correct position, a strong electric current is passed between them, killing the cancer cells in the tumour.
The procedure is performed under general anaesthetic, and takes approximately 2 hours. Patients usually require just one night in hospital following the procedure – a much shorter stay than those undergoing traditional surgery.
Dr Praveen Peddu, Consultant Radiologist at King’s, said the NanoKnife is a new option when traditional surgery isn’t an option: “The technology destroys soft tissue tumours with an electric current, which minimises the risk to other healthy organs nearby.
“This is particularly important when a tumour is in a difficult place and surgery would be more dangerous, such as next to a major blood vessel.”
Mr Parthi Srinivasan, Consultant Hepatobiliary and Pancreatic surgeon added , We are excited to have Nanoknife available for our patients. It is an important tool in our armoury against cancer.  Pancreatic cancer in particular has poor prognosis, unfortunately a  large proportion of patients are unsuitable for surgery. There is mounting evidence to suggest Nanoknife  improves duration of survival and quality of life in those group of patients. “It is great that we are able to offer suitable patients this alternative treatment option and hopefully save more lives.”